## Status Epilepticus (SE)

Last updated: December 19, 2020

<table>
<thead>
<tr>
<th>Definitions</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seizure cluster (s. acute repetitive seizures crescendo seizures, seizure flurries)</td>
<td>1</td>
</tr>
<tr>
<td>Status Epilepticus (SE)</td>
<td>1</td>
</tr>
<tr>
<td>Refractory SE</td>
<td>2</td>
</tr>
<tr>
<td>Super-refractory SE</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Epidemiology</th>
<th>3</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Etiology</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults</td>
<td>3</td>
</tr>
<tr>
<td>Children</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pathology</th>
<th>3</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Classification &amp; Clinical Features</th>
<th>4</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Differential Diagnosis</th>
<th>5</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Management</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Aid</td>
<td>6</td>
</tr>
<tr>
<td>1st line medications</td>
<td>8</td>
</tr>
<tr>
<td>2nd line medications</td>
<td>8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Management Following Status Epilepticus</th>
<th>15</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Prognosis</th>
<th>15</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Special Types</th>
<th>16</th>
</tr>
</thead>
<tbody>
<tr>
<td>Febrile status epilepticus</td>
<td>16</td>
</tr>
<tr>
<td>New-onset refractory status epilepticus (NORSE), Febrile infection–related epilepsy syndrome (FIRES)</td>
<td>17</td>
</tr>
<tr>
<td>Pyridoxine-dependent, pyridoxine-responsive epilepsies</td>
<td>18</td>
</tr>
</tbody>
</table>

### SEIZURE CLUSTER (S. ACUTE REPETITIVE SEIZURES CREScido SEIZURES, SEIZURE FLURRIES)

- acute episodes of consecutive seizures that occur within a short period of time with a patient regaining consciousness during the interictal period. These clusters are distinct from a person’s typical seizure pattern.
- when left untreated, can progress to status epilepticus.

### Status Epilepticus (SE)

\[
t_1 = \text{Length of seizure, when seizure should be considered abnormally prolonged}
\]

\[
t_2 = \text{Time after which ongoing seizure activity carries a risk of long-term consequences}
\]

\[t_1\] – time when seizure will likely be prolonged (time to initiate treatment)

\[t_2\] – time when seizures likely will leave long-term consequences (i.e. brief seizures probably are not harmful)
SE is failure of inhibitory mechanisms (thus, not every seizure proceeds to status); clustering - partial failure of inhibitory mechanisms.

**2015 ILAE task force definition** (t1 and t2 are different for different seizure types):

a) seizure lasting > 5 min for generalized tonic-clonic seizures (t2 = 30 mins)
b) seizure lasting > 10 min for focal seizures (t2 = 30-60 mins)
c) seizure lasting > 10-15 min for absence seizures (t2 unknown)

Other definitions:

a) persistent seizure activity after sequential administration of appropriate first and second-line AEDs
b) continuous seizure activity (clinical or electrical) ≥ 30 min.
c) repetitive seizures with incomplete neurological recovery interictally for period ≥ 30 min.

**Refractory SE**

(present in up to 23-43% patients) – if seizures continue despite two AEDs (1st and 2nd tier medications) after 30 minutes (for generalized seizures) or 60 minutes (for focal seizures) - mortality 17-39%.

**Super-refractory SE**

– if SE continues or recurs 24 hours after onset of anesthetic therapy or at withdrawal.
STATUS EPILEPTICUS

EPIDEMIOLOGY

- **INCIDENCE** - 15-20 cases per 100,000 people.
- most cases (70%) occur in **young children** (among children, 73% are < 5 yrs old)
- next most affected group is patients > 60 yrs age.

ETIOLOGY

1. **Acute CNS insults** (50%) - anoxia, head injury, stroke, neoplasm, infection, ethanol withdrawal or intoxication (!!!).
2. **Therapy related** (20%) - medication adjustments, **noncompliance** (most common cause in pre-known epileptic patients! esp. with abrupt phenobarbital withdrawal), intercurrent illness (preventing PO intake of meds), drug-drug interactions (lowering effectiveness of AEDs)
3. **Undetermined cause** (30%); may be as first manifestation of idiopathic epilepsy.

- in > 50% of cases, SE is **patient's first seizure** (i.e. > 50% SE patients do not have history of epilepsy); 1 out of 6 patients presenting with first time seizure will present in SE.
- 5-15% epileptic patients have had one or more SE episodes at some time.

ADULTS

- most common cause - **subtherapeutic AED levels** in patient with known seizure disorder.
- **cerebrovascular disease** predominates (25%) in **OLDER ADULTS**
- structural lesion is more likely than in pediatric subgroup.

CHILDREN

- in children < 1 yr age, 28% are secondary to **CNS infection**, 30% due to **electrolyte disorders**, 19% associated with **fever**.
  - **Fever & infection** are most common precipitants in children!

PATHOLOGY

- in animals, neurons begin to die after **20-60 minutes of continuous discharging** (precise time period in humans is unknown but irreversible changes begin to appear in neurons after as little as 20 minutes of convulsive activity; cell death is very common after 60 mins)
  - mean duration of SE in patients without neurologic sequelae is 1.5 hrs.
- significant increases in cerebral blood flow and metabolic rate during SE.
- neuron death may result from:
  1) metabolic **exhaustion**
  2) damage by **excitatory neurotransmitters**
- most vulnerable areas - hippocampus, amygdala, cerebellum, middle cortical areas, thalamus.
- acute **MACROSCOPIC changes** - venous congestion, small petechial hemorrhages, edema.
- **MICROSCOPIC changes**: ischemic cellular changes → microglial proliferation, neuronophagia → cell loss → increased numbers of reactive astrocytes.
**CLASSIFICATION & CLINICAL FEATURES**

a) **generalized** or **partial**

b) **convulsive** or **nonconvulsive**.

**Generalized convulsive SE (GCSE)** - convulsive activity accompanied by coma and epileptiform activity on EEG (EEG is not required for diagnosis):

*Most frequent (75%) and most dangerous type of SE!*

1) tonic-clonic
2) tonic
3) clonic
4) myoclonic

**Nonconvulsive SE** (clouding* of consciousness ± minor motor manifestations; i.e. abrupt-onset sustained confusional-delirious state):

*not complete loss (so sometimes called "twilight" form of SE)

1) **absence SE** (75% patients < 20 yrs; most other – older adults) - usually presents as one continuous episode (twilight state).
2) **complex partial SE** - usually recurring cycles of 2 distinctly separate phases (ictal and interictal).

N.B. patients can appear totally functional - clinical picture may be so subtle that only recognizable to friends and family!

- if patient is comatose, it most likely represents “burned-out” GCSE (i.e. subtle SE).
- **EEG is required for diagnosis** (and to distinguish two types):
  - **absence SE** – continuous 1-2.5 Hz generalized spike-wave activity ("spike-wave stupor");
  - **complex partial SE** - ictal activity is localized (usually to frontal or temporal lobes).

**Simple partial SE** – rare; diagnosis clinical (EEG frequently negative).

- **clonic simple partial SE** is called **Epilepsia Partialis Continua**.  see p. E9 >>
Status Epilepticus

GCSE manifestations change over time - paradoxical evolution of apparent clinical improvement (inexperienced clinician may stop treatment because of apparent improvement):

- SE begins with series of generalized tonic, clonic, or tonic-clonic seizures (OVERT SE);
  - each seizure is discreet; motor activity stops abruptly, coincident with end of electrographic seizure.
  - each convulsion is followed by gradual recovery, and then next seizure occurs.
- if SE is not treated, discrete convulsions give way to increasingly subtle clinical manifestations (SUBTLE SE); e.g. only nystagmoid jerks of eyes or shoulder twitching may be seen.
  - occasionally, subtle SE occurs without prior convulsive activity (e.g. in severe diffuse cerebral dysfunction).
- eventually, coma without motor activity is all that remains, although electrographic seizures persist (ELECTRICAL SE).
  N.B. status epilepticus should be suspected in any unexplained coma (e.g. patient stops having overt seizures, yet remains comatose)

Treatment should be continued until electrographic seizure activity* has resolved completely!

*CNS injury can occur even when patient is paralyzed with neuromuscular blockade but continues to have electrographic seizures.

GCSE produces SYSTEMIC EFFECTS:

Permanent brain damage is caused more by ongoing seizure activity than by systemic factors!

1) hypoxia, respiratory and metabolic acidosis
   - convulsive SE affects mechanical aspects of breathing (respiratory fatigue) + can cause neurogenic pulmonary edema + aspiration.
   - medications used for treating SE (esp. benzodiazepines and barbiturates) inhibit respiratory drive.
2) cerebral dysautoregulation, BP instability (↑ then ↓)
3) hyperpyrexia up to 42°C (motor activity + central sympathetic drive)
4) acute hypercatecholaminemia may trigger fatal cardiac arrhythmias.
5) hyperazotemia; hypokalemia; hyponatremia; hyperglycemia → hypoglycemia.
6) rhabdomyolysis → myoglobinuria, acute tubular necrosis, renal failure.
7) ↑↑↑ of plasma prolactin, glucagon, growth hormone, ACTH.
8) leukocytosis (bands should not be seen in absence of infection); modest CSF pleocytosis.

DIFFERENTIAL DIAGNOSIS

SE diagnosis depends on demonstrating ictal patterns in EEG!

Neuroimaging has no impact on immediate management until seizures are controlled.

MRI-DWI shows diffusion restriction (up to 3 days after status)

1. Nonepileptic phenomena (tremor, myoclonus, eye and oral-buccal movements that follow anoxia, brain stem or bilateral cerebral ischemia, drug overdose, severe metabolic disturbances) - difficult to differentiate clinically from nonconvulsive SE.
2. Prolonged psychogenic seizures.
**FIRST AID**

Acute life-threatening emergency that demands prompt diagnosis and treatment if severe neurological sequelae (pathologic brain changes) and death are to be minimized!

N.B. **SE duration is major determinant of morbidity and mortality!**

“Time is brain” - the sooner treatment is initiated, the better the chances of success, and the lower the risk for adverse consequences!

Nasal **MIDAZOLAM** (Nayzilam®) - nasal spray CIV, FDA approved for the acute treatment of **seizure clusters** in patients ≥ 12 years. see p. E3 >>

- **seizure activity ≥ 5-10 minutes** - treat as status, because most seizures must terminate spontaneously within 1-2 minutes.

  If seizure lasts > 2 minutes, place **intravenous line** and **draw blood** for tests. If seizure continues **beyond 5 minutes**, begin treatment with **benzodiazepine**

- **impending status epilepticus** - 3 or more TCS within 24-hour period (esp. if this represents increase from typical frequency); H: home treatment with one dose rectal **DIAZEPAM** gel (Diastat®) 10-20 mg (0.05-0.1 mg/kg) should be considered before transfer to ED.

  N.B. infusing buccal **MIDAZOLAM** into mouth (between gums and cheek) is twice as effective as rectal **DIAZEPAM**!

  If seizures continue, EMS can give IV/IM* **FOSPHENYTOIN**

  *gets absorbed in 5 mins, therapeutic level in 10 minutes

- admit to ICU, set a clock in motion.
- relapsing seizures in patient with **known seizure disorder** and **subtherapeutic AED levels** usually responds to bolus of maintenance AEDs, however, SE still should be treated by standard protocol.

N.B. use of neuromuscular blockers is inappropriate (unless needed for intubation – use short acting agent) because they do not stop seizure activity in brain (which is cause of brain damage!).

**Treatment for convulsive SE**

**STEP 1** (0-5 minutes of seizure) – **ABC + Coma** see p. S30 >>

1. **ABC** - secure oral airway (e.g. tongue may cause obstruction in younger patient - place nasopharyngeal airway), prevent aspiration (turn head to side, suction secretions), administer 100% O₂ (via properly fitting face mask); intubate if respirations compromised or if seizure persists > 30 min.
2. **Monitor** - ECG, SaO₂, vital signs.
3. **Blood tests** - bedside (fingerstick) glucose test; AEDs levels (if indicated), CBC, chemistries (electrolytes, Ca²⁺, Mg²⁺, BUN, creatinine, LFT), toxicological screens.
4. **Establish intravenous line** with normal saline.
5. **THIAMINE** 50-100 mg IV → **DEXTROSE** 50% 50 ml IV (D25 2 ml/kg in children).
6. Search for probable cause of SE (tests should not impede rapid and aggressive treatment!):
   1) obtain **history**
   2) perform **examination**
   3) some authors feel that **EEG monitoring** should be routine part of treatment; others use EEG only selectively (e.g. when GCSE diagnosis in doubt, assessing treatment adequacy).
STATUS EPILEPTICUS

In general, EEG has no role in management of GCSE!

4) **neuroimaging** should be done in all patients (except children with febrile SE); CT is sufficient to exclude acute brain lesion; MRI should be obtained later if CT was normal.

5) **lumbar puncture** is performed in any febrile patient (even if signs of meningitis are not present); if ICP↑ or mass lesion are suspected, antibiotics should be given immediately and CT scan obtained first.

WBC pleocytosis (up to 80) can occur following SE (benign postictal pleocytosis), but these patients should be treated with antibiotics until infection is ruled out by negative cultures!

- **acidosis** should not be treated (acidosis does not correlate with degree of neuronal injury + acidosis is anticonvulsant).
- **hyperthermia** should be treated aggressively (correlates with poor neurological outcome) - fans and antipyretics.

**STEP 2** (5-20 minutes of seizure) – *intravenous ANTICONVULSANTS* (terminate 80-97% cases):
- continuously monitor for respiratory depression, hypotension, arrhythmias.
- advanced cardiac life support must be ready!

2016 American Epilepsy Society (AES) guidelines:

Seizure > 5 minutes: IV bolus of **LORAZEPAM, DIAZEPAM, PHENOBARBITAL**, or IM **MIDAZOLAM**

Seizure > 20 minutes: → loading doses of **LEV** 60 mg/kg (max 4500 mg) or **VPA** 40 mg/kg (max 3000 mg) or **FOSPHENYTOIN** 20 mg PE/kg (max 1500 mg) are equally effective at stopping SE (if SE does not stop – it is RSE)

**N.B.** give **full dose at once** (do not break down in small doses to check for response)! – “time is brain and SE is not a benign condition”

- benzos IV in normal person risks respiratory depression; vs. in patient with status - benzos IV decrease the risk of needing intubation.

- in convulsive RSE, clinicians often add IVI of anesthetizing ASMs (“therapeutic coma”) such as MDZ, pentobarbital (PTB), or propofol (PRO) as third-line therapy – risk of serious adverse effects (3-9 fold relative increased risk of death, 4-fold increased incidence of infection, 7-fold relative increased risk of new disability).

- US Veterans Administration trial: in adults with CSE, first ASM worked in 55.5%, second ASM worked in another 7.0%, and the third ASM worked in only 2.3% of patients.

- in children, the second ASM appears less effective than the first, and there are no data about the third ASM.

- some experts advocate **early polytherapy** – to target multiple drivers of SE:

1. Inhibition of NMDA receptor may enhance potency of benzodiazepines (BDZ)
2. Calcineurin antagonists may enhance potency of BDZ
3. Inflammatory inhibitors (e.g. anakinra) may enhance BDZ effectiveness
4. Strategies to target extra-synaptic GABA(A) receptors (gamma-subunit lacking) may be effective later in SE management – anesthetics and neurosteroids
**1ST LINE MEDICATIONS**

- *rapid-acting* anticonvulsant - benzodiazepine (repeat once after 5 minutes PRN)

  a) **LORAZEPAM** – preferred agent (aborts SE in 97% cases, provides coverage for 12 hours)

  - 0.1 mg/kg (0.02-0.5 mg/kg in children); in general:
    - < 40 kg → 2 mg
    - > 40 kg → 4 mg (or 2+2 mg).
  - at < 2 mg/min - less respiratory depression, less fat soluble - slower, but **longer duration of action** – up to 2-3 hours!!!
    - N.B. even though lorazepam has much shorter T½ than diazepam, its effective half-life in brain is longer.
  - wait 1 minute for response; if seizures continue → given additional doses up to max 9 mg (adult)

  b) **MIDAZOLAM**

    N.B. IM midazolam 10 mg (5 mg for those < 40 kg) is more effective and faster to terminate seizures than IV lorazepam (at least in prehospital setting – RAMPART trial).

  ![Graph showing comparison of time from active treatment to cessation of convulsions for lorazepam and midazolam](image)

  c) **DIAZEPAM** 0.1-0.2 mg/kg (0.1-1.0 mg/kg in children) at 1-5 mg/min up to 10 mg; repeat once or twice q5-30min if seizures persist (aborts SE in 68% cases)

    - diazepam (high lipid solubility and rapid CNS entry) frequently abolishes seizure activity within minutes, only for seizures to recur within 30 minutes (as drug redistributes to other fatty tissues).
      - N.B. **DIAZEPAM** enters CNS slightly faster than **LORAZEPAM** but affords only 30 minute protection (vs. 12 hrs by **LORAZEPAM**).
    - if IV access is not obtainable, **DIAZEPAM** is drug of choice - may be given rectally (0.5 mg/kg, maximum 20 mg), endotracheally, intraosseously.

**2ND LINE MEDICATIONS**

- immediately next step (to prevent seizure recurrence) – **long-acting** anticonvulsant – equally effective alternatives:

  A. **FOSPHENYTOIN** 20 mg PE/kg (up to 150 mg PE/min – i.e. can be infused 3 times faster); PE = phenytoin equivalents.

    - N.B. administering **FOSPHENYTOIN** to patient who is taking PHT may raise level to point at which PHT actually becomes proconvulsant and cause cardiac arrest
    - contraindicated in drug-induced seizures.
    - if fosphenytoin is unavailable - **PHENYTOIN** 15-20 mg/kg load (up to 50 mg/min or 1 mg/kg/min); if seizures persist → additional 5-10 mg/kg boluses q20min (up to 30 mg/kg total or 30 μg/ml level)
N.B. phenytoin is incompatible with glucose-containing solutions!
- use continuous ECG and BP monitoring during infusion! (phenytoin is contraindicated in heart block).

B. **LEVETIRACETAM** 60 mg/kg (max 4500 mg/dose)

C. **VALPROATE** 30-40 mg/kg (slow onset of action is drawback).
- in hypersensitive to PHT or patients who already are taking PHT but in whom blood level of PHT is not yet known*
- drug of choice for MYOCLONIC STATUS; can add lorazepam or clonazepam to help with acute control.

Other alternatives:
**LACOSAMIDE** 10 mg/kg
**PHENOBARBITAL** 20 mg/kg (max 1000 mg/dose) – preferred for refractory febrile seizures in < 6 mos or drug-induced seizures.

N.B. **most common cause of treatment failure** - appropriate medication administered in *inadequate dosages* via *inappropriate route*!

**Established Status Epilepticus Treatment Trial (ESETT)**
- multicenter, randomized, double-blind trial

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Comments</th>
<th>Supporting References</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOS</td>
<td>20 mg/kg (PE) with maximum 1500 mg</td>
<td>Viewed as standard dose. PDR: Package insert</td>
<td></td>
</tr>
<tr>
<td>LEV</td>
<td>60 mg/kg with max 4500 mg</td>
<td>Highest approved dose for children, Published reports suggest safety of 4500 mg.</td>
<td></td>
</tr>
<tr>
<td>VPA</td>
<td>40 mg/kg with max 3,000 mg</td>
<td>Doses ranging between 15-45 mg/kg have been reported. Limdi, et al (2007)</td>
<td></td>
</tr>
</tbody>
</table>

Children and adults with benzodiazepine-refractory status epilepticus

Absence of clinically evident seizures and improved responsiveness at 60 min

- Levetiracetam 47% (68/145)
- Fosphenytoin 45% (53/118)
- Valproate 46% (56/121)

No significant difference in rates of seizure cessation or in safety
Status Epilepticus

Children vs Younger Adults vs Older Adults

Safety Outcomes Children n=229

- Life-threatening hypotension within 60 minutes
- Life-threatening cardiac arrhythmia within 60 minutes
- Acute respiratory depression
- Endotracheal intubation within 60 minutes
- Acute seizure recurrence 60 min to 12 hours
- Death

Younger Adults (18-65 years) n=196

- Life-threatening hypotension within 60 minutes
- Life-threatening cardiac arrhythmia within 60 minutes
- Acute respiratory depression
- Endotracheal intubation within 60 minutes
- Acute seizure recurrence 60 min to 12 hours
- Death
Convulsive Status Epilepticus Pediatric Trial (ConSEPT)
• randomly assigned 233 children to receive either levetiracetam or phenytoin.
• clinical cessation of seizure activity - 50% of the levetiracetam group and 60% of the phenytoin group (however, when the drugs were administered sequentially, the rate of seizure cessation rose to approximately 75%).

Emergency treatment with Levetiracetam or Phenytoin in convulsive Status Epilepticus in children trial (EcLiPSE)
• randomly assigned close to 300 children experiencing CSE to receive either levetiracetam or phenytoin.
• no statistically significant difference between the two groups was found in either the termination of the episode (CSE was terminated by levetiracetam in 70% of participants, and by phenytoin in 64% of participants) or the median time to seizure cessation, although there was a trend in favor of levetiracetam in both outcomes.

N.B. there is lack of evidence of what to do beyond 2nd line medications
STEP 3 – general anesthesia
1. Elective intubation (because benzodiazepine + barbiturate will cause respiratory depression) using rapid sequence technique (because all patients are considered as having full stomach).
2. Place arterial line + draw arterial blood gases.

STEP 4 – pharmacological COMA (administered by anesthesiologist):

**PENTOBARBITAL** 3-15 mg/kg load → 0.5-5 mg/kg/hr maintenance (titrated to burst-suppression near-electrocortical silence).

- treatment is continued for 6-48 hours.
- continuously monitor EEG (for recurrence of seizure activity).
- high risk of hypotension - ventilatory assistance and vasopressors are invariably required.
- other drugs used for refractory SE:
  a) **PROPOFOL** (1-2 mg/kg → 2-10 mg/kg/h)
  b) **MIDAZOLAM** (0.2 mg/kg → 0.75-45 μg/kg/min)
  c) **CARBAMAZEPINE**
  d) **OXCARBAZEPINE**
  e) **LACOSAMIDE**

40-60% success rate in SE, with low toxicity; TRENdS trial, which compared lacosamide with fosphenytoin in adults with nonconvulsive SE, showed success rates of 63% and 50%, respectively (no significant difference), with similar rates of adverse effects.

f) **BRIVARACETAM** (30% response rate and low toxicity).

g) **PERAMPANEL**; there’s not yet IV formulation, and the few available data in refractory SE show low effectiveness (5-20%).

h) **STIRIPENTOL** - moderate efficacy (30-50%) and low toxicity, though no IV formulation is available.
i) **Topiramate** (initial dose of 100 mg/d and high median maintenance dose of 400 mg/d); response rate 27.4%; hyperammonemia was a frequent adverse event (35.8%), mainly in combination with the administration of valproate.

Anne Fechner et al. Treatment of refractory and superrefractory status epilepticus with topiramate: A cohort study of 106 patients and a review of the literature. Epilepsia Nov 2019

j) **Lamotrigine**

k) **Diazepam** drip ≈ 2-3 mg/hr.

l) **Paraldehyde** 5% (150-200 mg/kg IV slowly for 15-20 min → 20 mg/kg/hr in concentration in glass* bottle); if administered rectally or IM can produce tissue damage and sloughing!

*drug is incompatible with plastic

m) **Lidocaine** (may cause seizures in toxic doses)

n) **Ketamine** - reserved for super-refractory SE (in 26 studies involving 303 super-refractory patients, ketamine treatment worked in 74%)

o) **Magnesium Sulfate** - may be effective in eclampsia.

### Additional Therapeutic Options

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Mechanism</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corticosteroids</td>
<td>Immune suppression 'Membrane stabilizing' effect</td>
<td>Consider if evidence of inflammation</td>
</tr>
<tr>
<td>PLEX / IVIG / Anakinra</td>
<td>Immunomodulation</td>
<td>Consider if evidence of inflammation</td>
</tr>
<tr>
<td>Ketogenic Diet</td>
<td>Unknown (? gap junctions)</td>
<td>Requires evidence of focality</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lesional: MRI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Non-lesional: MEG</td>
</tr>
<tr>
<td>Resective Surgery</td>
<td>Disrupt epileptogenic zone</td>
<td></td>
</tr>
<tr>
<td>Hypothermia</td>
<td>Neuroprotection</td>
<td>Immunosuppression, acidosis, elevated INR</td>
</tr>
<tr>
<td></td>
<td>Anticonvulsant effect?</td>
<td></td>
</tr>
</tbody>
</table>

**STEP 5 – general anesthesia** using inhaled anesthetic (**Halothane < Isoflurane**).
- novel therapeutic options (no systematic studies): transcranial magnetic stimulation, electroconvulsive therapy (shock therapy).
**STEP 6 – emergency surgery** (seizure focus resection, VNS at high stimulation parameters, etc).
- use intraop ECoG to delineate need to resect cortex.

### Treatment for nonconvulsive SE

- *may be treated less aggressively* - risk of neurological sequelae is significantly lower!
  - good guideline is not to worsen patient’s level of consciousness by pharmacologic means.

**ABSENCE SE**: low doses of benzodiazepine → dramatic improvement in mental state → **VALPROATE** IV or rectally (20-25 mg/kg in 50-mL solution over 10 minutes; repeat after 3 hours, then q6h) or oral ETHOSUXIMIDE.
  - no deaths or long-term morbidity have been reported!
  - differentiation from other causes is important - many mimics of absence SE can lead to irreversible neuronal damage if not aggressively treated!

**COMPLEX PARTIAL SE** – treatment as for GCSE:
  a) intravenous benzodiazepines.
  b) **FOSPHENYTOIN** (IM or IV)
  c) oral anticonvulsants
  - negative outcomes can occur!

**SIMPLE PARTIAL SE** – treatment less aggressive as for GCSE (e.g. if first-line drugs are ineffective, clinician may elect not to use general anesthetic agent to stop simple partial SE).
MANAGEMENT FOLLOWING STATUS EPILEPTICUS

- *idiopathic status epilepticus in previously healthy patient* → maintain **AED therapy for 3 months** → discontinue if remains asymptomatic.
- *other cases* – as general principles require. see p. E5 >>

### Prior to Wean… Optimize Conventional AED Therapy

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanism</th>
<th>Dosing</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valproate</td>
<td>Na, Ca channel blocker GABA&lt;sub&gt;A&lt;/sub&gt; modulator</td>
<td>30 mg/kg bolus, then 5 mg/kg/h infusion or 40-80 mg/kg/day q8h</td>
<td>• IV formulation not available in Canada</td>
</tr>
<tr>
<td>Topiramate</td>
<td>Na, Ca channel blocker GABA&lt;sub&gt;A&lt;/sub&gt; modulator AMPA, kainate modulator</td>
<td>10 mg/kg initial increase by 3 mg/kg q1-3 days</td>
<td>• PO/NG only • Metabolic acidosis</td>
</tr>
<tr>
<td>Levetiracetam</td>
<td>Ca channel blocker GABA modulator Glutamate modulator Synaptic vesicle 2A binding</td>
<td>10-40 mg/kg/day</td>
<td>• IV formulation now available in Canada</td>
</tr>
</tbody>
</table>

**PROGNOSIS**

Morbidity & mortality depend on:

1. **intervention speed** (duration > 1 hour carries poor prognosis)
2. **age** (outcome is better in children)
3. **etiology** (outcome is better with pre-existing idiopathic epilepsy, drug-induced SE).

**Mortality** (within 30 days): 20% (1-65%); 38% for refractory SE

- 27% for overt GCSE vs. 65% for *subtle GCSE*
- 4-6% in *children*, 13% in young adults, 38% in elderly, > 50% in *those > 80 years*.

1% of patients die during episode itself.

Morbidity and mortality is due to:

1. CNS injury from repetitive electric discharges
2. Systemic stress from seizure (cardiac, respiratory, renal, metabolic)
3. CNS injury by acute etiological insult

StEp Audit (2015):
SPECIAL TYPES

**FEBRILE STATUS EPILEPTICUS**

- often child’s first seizure.
- rarely stops spontaneously.
- most common life-threatening emergency in childhood.

MRI changes after febrile SE (predict development of hippocampal sclerosis):
**NEW-ONSET REFRACTORY STATUS EPILEPTICUS (NORSE), FEBRILE INFECTION–RELATED EPILEPSY SYNDROME (FIRES)**

- a clinical presentation, not a specific diagnosis:
  - NORSE - a clinical presentation in a patient without active epilepsy or other preexisting relevant neurological disorder who has NORSE without a clear acute or active structural, toxic, or metabolic cause. FIRES – NORSE preceded by a febrile infection.
  - pathophysiology is largely unknown (autoimmune encephalitis in only half of cases); high levels of cytokines (IL-6 and TNFα), in the serum and CSF.
    - one study identified an association between FIRES and polymorphisms in the IL-1 receptor antagonist gene.
  - treatment - immune therapies:
    - steroids, intravenous immunoglobulins, and plasma exchange – disappointing.
    - ketogenic diet (anti-inflammatory effects) - more efficacious.
○ **ANAKINRA** - successful in a single case report.

○ **TOCILIZUMAB** (humanized monoclonal antibody against the IL-6 receptor) - SE was terminated after 1 or 2 doses of tocilizumab in 6 patients (out of 7) with a median interval of 3 days from the initiation

**PYRIDOXINE-DEPENDENT, PYRIDOXINE-RESPONSIVE EPILEPSIES**

- should be considered in children (birth - 3 yo) with refractory seizures and no imaging lesion or other acquired cause of seizures.

**BIBLIOGRAPHY** for ch. “Epilepsy and Seizures” → follow this [LINK](#)